prostate cancer

Medivation retreats after J&J beefs up prostate cancer slate

Medivation retreats after J&J beefs up prostate cancer slate

The Fly on the Wall

J&J to Buy Aragon Pharmaceuticals for Cancer Candidate

J&J to Buy Aragon Pharmaceuticals for Cancer Candidate

Bloomberg

3 FDA Stories You Missed This Week

3 FDA Stories You Missed This Week

Motley Fool

Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer

Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer

Yahoo/BusinessWire

Progenics Pharmaceuticals' Data From a Phase 1 Study of PSMA ADC Presented at ASCO 2013

Progenics Pharmaceuticals' Data From a Phase 1 Study of PSMA ADC Presented at ASCO 2013

Yahoo/GlobeNewsWire

Bayer Shakes Up Prostate Cancer Market

Bayer Shakes Up Prostate Cancer Market

Motley Fool

Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug

Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug

Bloomberg

Astellas forecasts big sales growth as prostate drug catches hold

Astellas forecasts big sales growth as prostate drug catches hold

Fierce Pharma

Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation

Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation

Yahoo/Minyanville

Medivation, Astellas Pharma provide update on Phase 3 PREVAIL

Medivation, Astellas Pharma provide update on Phase 3 PREVAIL

Yahoo/Fly on the Wall